Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Investor Growth Capital
Mandate

Vinge advises Investor Growth Capital

January 30, 2009

Vinge has advised Investor Growth Capital in connection with its investment in Synosia Therapeutics. Synosia Therapeutics is a company which develops and intends to commercialise innovative and clinically differentiated products for unfulfilled medical requirements within psychiatry and neurology.
 
Vinge’s team consisted of responsible partner Johan Winnerblad together with associate Karl Svantema.

Related

Vinge has advised private equity firm Stirling Square Capital Partners

 Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023

Vinge advises Stendörren in connection with issuance of green notes and tender offer

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
September 21, 2023

Vinge has advised Elektroskandia in connection with its majority investment in Aprilice

 Vinge has advised Elektroskandia (a Sonepar company) in connection with its acquisition of 70% of the shares in Aprilice, one of the leading solar energy platforms in Northern Europe.
September 20, 2023